RecruitingNCT07311356

Prognosis of Early-onset Anorexia Nervosa

Evalutation of the Prognosis and Quality of Life of Patients Hospitalized for Early-onset Anorexia Nervosa


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

140 participants

Start Date

Dec 5, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The AM2P study aims to evaluate the long-term prognosis and quality of life of patients with early-onset anorexia nervosa, assessed 4 to 9 years after hospitalization. Prognosis will be determined using a composite outcome measure based on questionnaire responses and health indicators, including body mass index (BMI). In addition, the study will examine the patients' overall physical condition both at the time of assessment and during the interval between their last hospitalization and the present evaluation.


Eligibility

Min Age: 0 YearsMax Age: 30 Years

Inclusion Criteria4

  • First full hospitalization in the eating disorders unit (EDU) at Robert Debré Hospital and diagnosis of AMP from 2016 to 2021
  • No objection from the minor to the study
  • Proficiency and understanding of the French language
  • Access to digital technology (computer, smartphone, tablet, etc.)

Exclusion Criteria1

  • Primary diagnosis of ARFID, other unspecified eating disorder

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hopital Robert Debre - AP-HP

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07311356


Related Trials